204 related articles for article (PubMed ID: 32905826)
1. Dual TBK1/IKKε inhibitor amlexanox mitigates palmitic acid-induced hepatotoxicity and lipoapoptosis in vitro.
Zhou Z; Qi J; Lim CW; Kim JW; Kim B
Toxicology; 2020 Nov; 444():152579. PubMed ID: 32905826
[TBL] [Abstract][Full Text] [Related]
2. Amlexanox reversed non-alcoholic fatty liver disease through IKKε inhibition of hepatic stellate cell.
He Q; Xia X; Yao K; Zeng J; Wang W; Wu Q; Tang R; Zou X
Life Sci; 2019 Dec; 239():117010. PubMed ID: 31672578
[TBL] [Abstract][Full Text] [Related]
3. Dual TBK1/IKKɛ inhibitor amlexanox attenuates the severity of hepatotoxin-induced liver fibrosis and biliary fibrosis in mice.
Zhou Z; Qi J; Zhao J; Lim CW; Kim JW; Kim B
J Cell Mol Med; 2020 Jan; 24(2):1383-1398. PubMed ID: 31821710
[TBL] [Abstract][Full Text] [Related]
4. Amlexanox ameliorates acetaminophen-induced acute liver injury by reducing oxidative stress in mice.
Qi J; Zhou Z; Lim CW; Kim JW; Kim B
Toxicol Appl Pharmacol; 2019 Dec; 385():114767. PubMed ID: 31697998
[TBL] [Abstract][Full Text] [Related]
5. Long-term subcutaneous injection of lipopolysaccharides and high-fat diet induced non-alcoholic fatty liver disease through IKKε/ NF-κB signaling.
He Q; Zeng J; Yao K; Wang W; Wu Q; Tang R; Xia X; Zou X
Biochem Biophys Res Commun; 2020 Nov; 532(3):362-369. PubMed ID: 32883523
[TBL] [Abstract][Full Text] [Related]
6. The Specific IKKε/TBK1 Inhibitor Amlexanox Suppresses Human Melanoma by the Inhibition of Autophagy, NF-κB and MAP Kinase Pathways.
Möller M; Wasel J; Schmetzer J; Weiß U; Meissner M; Schiffmann S; Weigert A; Möser CV; Niederberger E
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32630674
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of TBK1 by amlexanox attenuates paraquat-induced acute lung injury.
Wang N; Li Y; Wang X; Ma Z; Wang Y; Zhang C; Yuan Y; Zhao M
Toxicology; 2020 Oct; 443():152555. PubMed ID: 32763286
[TBL] [Abstract][Full Text] [Related]
8. Encephalomyocarditis virus 3C protease attenuates type I interferon production through disrupting the TANK-TBK1-IKKε-IRF3 complex.
Huang L; Xiong T; Yu H; Zhang Q; Zhang K; Li C; Hu L; Zhang Y; Zhang L; Liu Q; Wang S; He X; Bu Z; Cai X; Cui S; Li J; Weng C
Biochem J; 2017 Jun; 474(12):2051-2065. PubMed ID: 28487378
[TBL] [Abstract][Full Text] [Related]
9. Treatment of cigarette smoke extract and condensate differentially potentiates palmitic acid-induced lipotoxicity and steatohepatitis in vitro.
Zhou Z; Kim JW; Zhao J; Qi J; Choi SJ; Lim CW; Lee MY; Lee K; Kim B
Toxicol In Vitro; 2018 Oct; 52():33-40. PubMed ID: 29864471
[TBL] [Abstract][Full Text] [Related]
10. TBK1 and IKKε Act Redundantly to Mediate STING-Induced NF-κB Responses in Myeloid Cells.
Balka KR; Louis C; Saunders TL; Smith AM; Calleja DJ; D'Silva DB; Moghaddas F; Tailler M; Lawlor KE; Zhan Y; Burns CJ; Wicks IP; Miner JJ; Kile BT; Masters SL; De Nardo D
Cell Rep; 2020 Apr; 31(1):107492. PubMed ID: 32268090
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological activity of substituted 2-amino-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid derivatives as inhibitors of the inflammatory kinases TBK1 and IKKε for the treatment of obesity.
Beyett TS; Gan X; Reilly SM; Gomez AV; Chang L; Tesmer JJG; Saltiel AR; Showalter HD
Bioorg Med Chem; 2018 Nov; 26(20):5443-5461. PubMed ID: 30270002
[TBL] [Abstract][Full Text] [Related]
12. Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction.
Cruz VH; Arner EN; Wynne KW; Scherer PE; Brekken RA
Mol Metab; 2018 Oct; 16():139-149. PubMed ID: 29935921
[TBL] [Abstract][Full Text] [Related]
13. Synoviocyte innate immune responses: TANK-binding kinase-1 as a potential therapeutic target in rheumatoid arthritis.
Hammaker D; Boyle DL; Firestein GS
Rheumatology (Oxford); 2012 Apr; 51(4):610-8. PubMed ID: 21613249
[TBL] [Abstract][Full Text] [Related]
14. IKKε aggravates inflammatory response via activation of NF-κB in rheumatoid arthritis.
Zhou LF; Zeng W; Sun LC; Wang Y; Jiang F; Li X; Zheng Y; Wu GM
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(7):2126-2133. PubMed ID: 29687872
[TBL] [Abstract][Full Text] [Related]
15. Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKK
Beyett TS; Gan X; Reilly SM; Chang L; Gomez AV; Saltiel AR; Showalter HD; Tesmer JJG
Mol Pharmacol; 2018 Oct; 94(4):1210-1219. PubMed ID: 30082428
[TBL] [Abstract][Full Text] [Related]
16. Akt phosphorylation regulated by IKKε in response to low shear stress leads to endothelial inflammation via activating IRF3.
Zhu L; Yang H; Chao Y; Gu Y; Zhang J; Wang F; Yu W; Ye P; Chu P; Kong X; Chen S
Cell Signal; 2021 Apr; 80():109900. PubMed ID: 33370582
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the protein kinase IKKepsilon attenuates neuropathic pain in mice.
Möser CV; Möller M; Fleck SC; Thomas D; Geisslinger G; Niederberger E
Neuropharmacology; 2019 Mar; 146():198-211. PubMed ID: 30528326
[TBL] [Abstract][Full Text] [Related]
18. DDX19 Inhibits Type I Interferon Production by Disrupting TBK1-IKKε-IRF3 Interactions and Promoting TBK1 and IKKε Degradation.
Zhang K; Zhang Y; Xue J; Meng Q; Liu H; Bi C; Li C; Hu L; Yu H; Xiong T; Yang Y; Cui S; Bu Z; He X; Li J; Huang L; Weng C
Cell Rep; 2019 Jan; 26(5):1258-1272.e4. PubMed ID: 30699353
[TBL] [Abstract][Full Text] [Related]
19. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation.
Clark K; Plater L; Peggie M; Cohen P
J Biol Chem; 2009 May; 284(21):14136-46. PubMed ID: 19307177
[TBL] [Abstract][Full Text] [Related]
20. Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKε and TBK1.
Mowers J; Uhm M; Reilly SM; Simon J; Leto D; Chiang SH; Chang L; Saltiel AR
Elife; 2013 Dec; 2():e01119. PubMed ID: 24368730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
